Annual Report 2020 - Hoosier Cancer

Annual Report 2020

Board of Directors

Hoosier Cancer Research Network’s vision and mission is to form

unparalleled relationships between academic, community,

pharmaceutical, and biotech collaborators with the goal of advancingcancer research, education, and patient advocacy.

Our highly qualified team provides comprehensivestudy management and support, from conception and study

design through project completion and publication.

Christopher Fausel, PharmD, MHA, BCOP, Chair

Shadia Jalal, MD, Chief Scientific Officer

Alesha Arnold, RN

Annette Moore, MD, Secretary

Christopher Wayne, MS, MBA, FACHE, CMPE, Treasurer

Richard Zellars, MD

Noah Hahn, MD

Christopher LeMasters, MBA

Ted StansburyPatrick Loehrer, Sr., MD

Timothy Ratliff, PhD

Kerry Bridges, MBA, RN, CCRC

A s part of the nation’s workforce on the front lines of patient care, we

know all too well how challenging this past year has been on our healthcare system. Many of our colleagues have taken on new responsibilities to ensure the best possible care for all patients who walk through the doors of our hospitals and clinics.

More than ever before, this past year has crystallized the importance of establishing and strengthening collab-orations across the hallway and across institutions, and we are deeply proud of the role Hoosier Cancer Research Network has played in ensuring such collaborations not only exist but also thrive in times like these.

Together, all members of the HCRN team have played their part, and then some, to bring hope to patients. We thank our academic and community sites, sponsor-investigators, site PIs and co-PIs, study teams, funders, and the talented and committed leadership and staff of Hoosier Cancer Research Network for ensuring we never missed a beat during 2020. Most importantly, we thank each and every patient who enrolled in a clinical trial. Your participation is a gift to future generations of cancer patients and enables researchers to develop safer and more effective ways to treat cancer.

We know that cancer never eases its assault on our loved ones. As long as there is progress to be made, together we will continue the good work that must be done.

Christopher A. Fausel, PharmD, MHA, BCOPOncology Precision Genomics Pharmacist,Indiana University Melvin and Bren SimonComprehensive Cancer Center

Shadia I. Jalal, MDAssociate Professor of MedicineIndiana University School of Medicine

One Team. Infinite Possibilities.

Chairman and CSOPerspectives

I n the years since I joined Hoosier Cancer Research Network in 2006, change has been a common thread that has woven through our “story.” The

past year, perhaps more than any other, has reminded me how important it is for organizations to be nimble and resilient in the face of many challenges.

HCRN is fortunate to be guided by a board of directors who understand the complex and rapidly evolving space for conducting multi-center, inves-tigator-initiated clinical research studies. Our management team and staff represent decades of expertise and leadership in highly specialized areas, strengthened by a culture of flexibility that embraces change when required to meet the needs of the moment.

While being mindful that many organizations did not survive the year or sig-nificantly curtailed their scope of operations, I am deeply grateful that HCRN held steady throughout, remained true to our founding mission, and emerged stronger in many respects than when the year began. One of the greatest lessons we have learned is that, while the COVID-19 pandemic created many hurdles that had to be cleared for research operations to function normally, it did not slow the pace of our research development. Our working groups grew steadily throughout 2020, both in participation and in the number of LOIs received. With strong continuing support from industry funders, we ended the

year with 71 active studies and 21 approved LOIs: both unprecedented numbers in our organization’s history.

In the 35+ years since our founding, HCRN has held to a central purpose: to support investigators in managing their multi-center clinical trials. Many of our sponsor-investigators and Clinical Trial Working Group co-chairs are pictured on the cover of this report, and throughout the following pages. We are indebted to them, both for their expertise and for their commitment to building a strong network for collaborative cancer research.

To all our members, supporters, and friends: We hope you enjoy this reflection on our shared accomplishments from the past year. From my perspective, what we have done together, and will yet do, far outshines the challenges that we will meet along the way.

Cyndi Burkhardt, RNExecutive DirectorHoosier Cancer Research Network

Executive DirectorPerspectives

CareyAnders, MDDuke Cancer Institute

Breast Cancer CTWG Co-chairs

Erica Stringer- Reasor, MD University of Alabama at Birmingham

Breast Cancer CTWGat a glance

50+member investigators

30+institutions represented

6active studies & approved LOI as of 12/31/2020

Learn more:hoosiercancer.org/breast

BREAST CANCERClinical Trial Working Group

A Message from our Co-Chairs

The HCRN Breast Cancer Working Group strengths include multidisci-plinary membership that promotes transdisciplinary concepts. The team has also surveyed membership to determine the areas of interest that are most needed in the field of breast oncology and have tailored our port-folio to those needs. We have also seen increasing participation among members, with new members added frequently to build on the group’s collective expertise. The year 2020 was challenging on many fronts. Despite the many de-mands among members, the working group remained quite active with consistent participation on our calls, momentum for existing LOIs and protocols, and submission of new proposals. Despite the challenges on each individual, the working group remained cohesive and continues to move forward to develop innovative protocols for our patients with breast cancer. As our working group is relatively young, we have many concepts ap-proved and in development. The past two years have been focused on building our portfolio, and we see 2021 as a year of implementation. We are hopeful that by the end of the year, many of our approved protocols will be open to accrual and actively recruiting. To round out our portfolio, we would love to see more momentum in the surgical oncology and translational space. Our portfolio has many inno-vative concepts across medical and radiation oncology. Engaging our surgical and translational colleagues is a goal for our future.

2020 Publications and Presentations

JAMA Oncology Manuscript:

• Radovich M, Jiang G, Hancock BA, et al. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Pre-planned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020;6(9):1410–1415. doi:10.1001/jamaoncol.2020.2295

San Antonio Breast Cancer Symposium:

• Spotlight Poster Discussion Session: M Radovich, N Kassem, G Jiang, BA Hancock, BP Schneider. Circulating TP53 mutations in TNBC after neoadjuvant chemotherapy is associated with rapid disease recur-rence: Correlative analysis from clinical trial BRE12-158.

GI CTWGat a glance




Learn more:hoosiercancer.org/gi

GI CTWG Co-chairs

Bassel El-Rayes, MDEmoryUniversity

Richard Kim, MDMoffitt Cancer Center

Autumn J. McRee, MDUniversity of North Carolina

GASTROINTESTINALClinical Trial Working Group


The GI Clinical Trial Working Group is both productive as well as collaborative. We bring a wide berth of expertise in both clinical trial design and transla-tional oncology to our trials that allows for innovative correlative science to be embedded within our trials. Senior and junior faculty work together in such a way that the expertise of the more seasoned trialists is harnessed to train the next generation of GI oncology clinical researchers. We design trials that we know our group can enroll robustly and have a well documented track record of completing and publishing trials. As the clinical care of our cancer patients underwent huge changes in response to the COVID-19 pandemic, how to continue to provide access to clinical trials for these patients was a top priority for our working group. We discussed challenges that each site was experiencing on our monthly calls and communicated realistic expectations to both the study funders and the sites in terms of enrollment and data collection. Fortunately, despite the need to remain nimble and pivot quickly, we still saw steady clinical trial enrollment on several trials with a published abstract at ASCO GI. This past year has brought more members from high volume cancer centers to our group, providing a fresh set of ideas for new clinical trial designs. Additionally, we have partnered with both industry and institutional labs to allow for more robust and novel correlative studies to be performed on our study samples, including liquid biopsy ctDNA evaluation, microbiome assays, and immunogenomics. Proposals targeting metastatic colorectal cancer are always in high demand given the large numbers of patients we see in the clinic with refractory dis-ease. In addition, new targets in biliary cancer will inevitably lead to ques-tions regarding combining targeted therapies with chemotherapy and immu-notherapy for these patients. We also have interest in targeting cancers with HRD signatures as well as rationale combinations of immunotherapy agents in gastroesophageal cancer.


Gastrointestinal Cancers Symposium:

• Trials in Progress Poster: A phase II study evaluating safety and effica-cy of niraparib in patients with previously treated homologous recom-bination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma: ESO17-325.

GU CTWGat a glance




Learn more:hoosiercancer.org/gu

Matthew Galsky, MDIcahn School of Medicineat Mount Sinai

GU CTWG Co-chairs

Noah M. Hahn, MDJohns Hopkins University

Guru Sonpavde, MDDana-Farber Cancer Institute

GENITOURINARYClinical Trial Working Group


The Genitourinary Clinical Trial Working Group is very active with a steady stream of concepts from our engaged investigators. Activated protocols have accrued well overall. Additionally, our studies have largely involved rich correlatives and specimen collection. Like others during the pandem-ic, we shifted to largely remote meetings and we moved to monthly rather than quarterly meetings. Each protocol within the portfolio was modified to account for COVID-related stipulations such as allowing remote visits and broadening windows for study activities. A primary goal for the working group in the coming year is to diversify the portfolio. While the bladder portfolio is particularly strong, we hope to further build the RCC and prostate cancer portfolios. We will also consider adaptive trial platforms across tumor types, especially in bladder can-cer where we do a lot of neoadjuvant treatment. For each protocol that moves forward through our working group, we plan to embed well-round-ed protocol teams that include junior investigators and potentially trans-lational, imaging, and quality of life investigators, as applicable, to allow broader involvement in concept and protocol development. Additionally, we plan to set up regular networking opportunities with investigators and industry collaborators to discuss concepts and potential new protocols.


Journal of Clinical Oncology Manuscript:• Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Vs.

Placebo After First-Line Chemotherapy in Patients w/ Metastatic Urothelial Can-cer. DOI: 10.1200/JCO.19.03091 Journal of Clinical Oncology: GU14-182.

Genitourinary Cancers Symposium:• TIP Poster: Phase II trial of atezolizumab plus chemotherapy after progression

on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with ad-vanced urothelial carcinoma: GU17-295.

ASCO Annual Meeting:• Oral Abstract: Phase II study of nivolumab and salvage nivolumab + ipilimumab

in treatment-naïve patients with advanced renal cell carcinoma: GU16-260.• Poster Discussion: Phase II neoadjuvant gemcitabine and pembrolizumab for

locally advanced urothelial cancer: Interim results from the cisplatin-ineligible cohort of GU14-188.

• Poster: Phase Ib/II neoadjuvant pembrolizumab and chemotherapy for locally ad-vanced urothelial cancer: Final results from cisplatin-eligible cohort of GU14-188.

ESMO Annual Meeting:• Poster: A Phase Ib/2 study of neoadjuvant pembrolizumab and chemotherapy

for locally advanced Urothelial Cancer: GU14-188.• Poster: A phase II study of cabozantinib in combination with atezolizumab as

neoadjuvant treatment for muscle-invasive bladder cancer (ABATE): GU18-343.

Society of Urologic Oncology Annual Meeting:• Poster: Phase 1 trial of durvalumab in combination with BCG or external beam

radiation in BCG-unresponsive non-muscle invasive bladder cancer patients: GU16-243 (ADAPT-BLADDER Trial).

Thoracic CTWGat a glance




Learn more:hoosiercancer.org/thoracic

THORACICClinical Trial Working Group

Greg Durm, MDIndiana University School of Medicine

Thoracic CTWGCo-chairs

Mary Jo Fidler, MDRush Medical College


One of the key strengths of the HCRN Thoracic Clinical Trial Working Group is its breadth and diversity. We have academic centers that have accrued quickly to innovative trials in select patient populations and com-munity sites that give a real-world perspective to our clinical trials port-folio. The nimble nature of the working group allows concepts to move quickly from investigator-initiated LOI submission to fully funded protocols and clinical trials open for enrollment.

We have always communicated remotely, as our member investigators represent institutions nationwide. With the challenges of the past year we have been able to incorporate better remote conferencing tools to make our meetings more engaging and productive. The working group has a broad portfolio, but we see opportunities in a few key areas. Particularly, we can develop impactful studies in the head and neck space, and we can increase our multimodality studies and an-swer questions relating to supportive care with our patient populations.


RyanGentzler, MDUniversity of Virginia Schoolof Medicine

Cancer Manuscript:• Durm, GA, Jabbour, SK, Althouse, SK, Liu, Z, Sadiq, AA, Zon, RT, Jalal,

SI, Kloecker, GH, Williamson, MJ, Reckamp, KL, Langdon, RM, Kio, EA, Gentzler, RD, Adesunloye, BA, Harb, WA, Walling, RV, Titzer, ML, Hanna, NH. A phase 2 trial of consolidation pembrolizumab following concur-rent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN14-179. Cancer. 2020: 126: 4353– 4361. https://doi.org/10.1002/cncr.33083.

Clinical Lung Cancer Manuscript:• B Anouti, S Althouse, G Durm, N Hanna. Prognostic Variables Associat-

ed With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Re-search Network LUN 14-179. Clinical Lung Cancer, Volume 21, Issue 3, 2020, Pages 288-293, ISSN 1525-7304, https://doi.org/10.1016/j.cllc.2019.06.009.

ASCO Annual Meeting:• Poster Session: N Shukla, SK Althouse, AA Sadiq, SI Jalal, SK Jabbour,

R Zon, GH Kloecker, WB Fisher, KL Reckamp, EA Kio, RM Langdon, B Adesunloye, RD Gentzler, NH Hanna, GA Durm. The association between immune- related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN14-179.

Clinical Trial Working GroupsCorrelative Sciences CTWGat a glance



Learn more:hoosiercancer.org/correlative

Correlative Sciences CTWG Co-chairs

David J. McConkey, PhDJohns Hopkins University

Thomas G. Sors, PhDPurdue University

Melanoma CTWGCo-chairs

Melanoma CTWGat a glance




Learn more:hoosiercancer.org/melanoma

Timothy Kuzel, MDRush University

Ragini R. Kudchadkar, MDEmory University

April Salama, MDDuke University

A Message From our Correlative Sciences Co-Chairs

The HCRN Correlative Sciences working group includes a wide diversity of oncologists and basic science investigators who provide expertise on the best correlative questions to ask and the most appropriate samples to be collected for the studies we review. This diverse, nationwide community allows us to be versatile in the support we provide for oncology trials.

Over the past year, our team continued our recurrent virtual calls and worked closely with investigators as they planned their studies. We introduced speak-ers who highlighted technologies relevant to correlative sciences. In the com-ing year, we will explore opportunities to leverage existing collaborations be-tween institutions and health networks to strengthen the statistical robustness of our studies. We also plan to increase our collaboration with data scientists throughout the HCRN network.

Myeloid CTWGat a glance


8institutions represented

Learn more:hoosiercancer.org/myeloid

Myeloid CTWGCo-chairs

Joshua Zeidner, MDUniversity of North Carolina

Matthew Foster, MDUniversity of North Carolina

Research CollaborationsBig Ten Cancer Research Consortium (Big Ten CRC)

The Big Ten Cancer Research Consortium was created in 2013 to transform the con-duct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten univer-sities. The goal of the Big Ten CRC is to create a unique team-research culture to

drive science rapidly from ideas to new approaches to cancer treatment. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer. Learn more: bigtencrc.org.

HCRN serves as administrative headquarters for the Big Ten CRC.

Translational Breast Cancer Research Consortium (TBCRC)

The Translational Breast Cancer Research Consortium is a collaborative group found-ed in 2005 to conduct innovative and high-impact clinical trials for breast cancer. The TBCRC is composed of 19 clinical sites; five core working groups focusing on correlative science and breast cancer phenotypes; two interest groups focusing on patient-reported outcomes and immuno-oncology; working groups for patient advocates, study coordina-tors, and contracts/administrators; and a central office. Collectively, these groups work to

foster trial development in a collegial environment that enhances cross-institutional collaboration. Learn more: pub.emmes.com/study/bcrc/.

HCRN provides trial management and support to the TBCRC.

Bladder Cancer Genomics Consortium (BCGC)

The Bladder Cancer Advocacy Network launched the Bladder Cancer Genomics Con-sortium in 2017. The BCGC’s ultimate goal is to provide the opportunity for every patient to be an exceptional responder to personalized therapy while advancing collaborative research to support the development of life-saving treatments for bladder cancer. Learn more: bcan.org/bladder-cancer-genomics-consortium/.

HCRN developed and manages a genomically driven sample collection study for the BCGC.

Midwest Melanoma Partnership (MMP)

The Midwest Melanoma Partnership (MMP) is a multi-institutional collaboration of physicians, scientists, and patient advocates dedicated to the development of improved therapies for patients with malignant melanoma. Learn more: midwestmelanoma.org.

HCRN provides trial management and support to the MMP.

Big Ten Cancer Research Consortium

Big Ten CRCat a glance

300+investigators in Clinical Trial Working Groups

500+patients enrolled to date on Big Ten CRC studies

30+Big Ten CRC studies opened to date

Learn more:www.bigtencrc.orgfacebook.com/bigtencrctwitter.com/bigtencrc

The Big Ten cancer centers have united . . .

to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The goal of the Big Ten Cancer Research Consortium is to create a unique team-research culture to drive science rapidly from ideas to new approaches to cancer treatment. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.

2020 Publications and PresentationsManuscripts:

• Journal of Clinical Oncology (BTCRC-GU14-003)

Gastrointestinal Cancers Symposium:• 2 posters (BTCRC-ESO14-012, BTCRC-GI18-149)

Genitourinary Cancers Symposium:• 1 poster (BTCRC-GU15-023)

ASCO Annual Meeting:• 2 poster discussions (BTCRC-LUN16-081, BTCRC-GYN15-013)• 2 posters (BTCRC-ESO14-012, BTCRC-AML17-113)

ESMO:• 1 poster (BTCRC-GU16-043)

Studies Opened to Accrual in 2020

LUN18-357

Title: Induction durvalumab fol-lowed by chemoradiation and con-solidation durvalumab (MEDI4736) for stage III non-small cell lung cancer.

Sponsor-Investigator: Rachel E. Sanborn, MDLead Institution: Providence Cancer Institute

GI18-333

Title: Phase 2 study of novel SE-QUEnced immunotherapy (pem-brolizumab) with anti-angiogenesis and chemotherapy in advanced gas-tric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL).

Sponsor-Investigator: Harry Yoon, MDLead Institution: Mayo Clinic

GI19-405

Title: A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Un-resectable Hepatocellular Carcino-ma (HCC).

Sponsor-Investigator: Aiwu Ruth He, MDLead Institution: Georgetown University

GU18-343

Title: A Phase 2 Study of CAbozan-tinib in Combination With Atezoli-zumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE).

Sponsor-Investigator: Deepak Kilari, MDLead Institution: Froedtert & Med. College of Wisconsin

BTCRC-LYM17-145

Title: Phase Ib dose de-escalation study of PI3K alpha/delta inhibitor Copanlisib given in combination with immunotherapeutic agents Nivolum-ab and Rituximab in patients w/ re-lapsed/refractory indolent lymphoma.

Sponsor-Investigator: Tycel Phillips, MDLead Institution: University of Michigan

BTCRC-GI15-067

Title: A phase II study to evaluate the efficacy of liposomal irinotec-an in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pan-creatic carcinoma.

Sponsor-Investigator: Nelson S. Yee, MD, PhD, RPhLead Institution: Penn State Cancer Institute

BTCRC-LUN18-153

Title: A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm.

Sponsor-Investigator: Greg Durm, MDLead Institution: Indiana University

BTCRC-LUN19-396

Title: Phase II Study of Adjuvant Treatment w/ Cisplatin-based Chemo-therapy + Concomitant Atezolizumab in pts w/ Stage I (Tumors ≥ 4cm), IIA, IIB, Select IIIA [T3N1, T4N0-1] Resect-ed NSCLC and Clearance of ctDNA.

Sponsor-Investigator: Nasser Hanna, MDLead Institution: Indiana University

T hank you to all who have contributed to Hoosier Cancer Research Network. We are grateful for your commitment of time and resources to help us fulfill our mission. Your generous sup-

port strengthens our ability to fund investigator-initiated research. Learn how you can contribute at www.hoosiercancer.org/make-a-difference/.

Contributions Received in 2020

Amazon SmileEvangeline AntonopoulosJoLynn BahrThe Benevity Community Impact Fund (Microsoft)The Blackbaud Giving FundBrent Barta (West 10th Dental Group)Maura Buckley — In memory of George F. BuckleyCynthia Burkhardt — In memory of

Mr. John H. WaffleNoreen Cahalane (Merz Branding)Anita CamicAli Coffey — In memory of Martha BlankKenneth CornettaRandal Dillinger — In memory of Bryn MarlowKaren DutcherChristopher A. Fausel — In memory of

Mr. Gerald W. FauselFidelity Charitable — In honor of Dr. John EliadesBill, Bob, John and Janet Fisher — In memory of

Mrs. Fannie BeallCharles Fletcher FoxTom Goins — In honor of Dr. Jeanne M. SchilderSara Jo GrethleinPamela Griffin — In memory of Edward J. GriffinPatricia KneeboneChris LeMastersAshley Lucas — In honor of Mr. Mark BreedloveCara A. Martin — In memory of Skip Herring

Julie Martin — In honor of Dr. Jeanne M. SchilderMary A. Maxwell — In honor of

Dr. Jeanne M. SchilderSarah MaxwellRakesh MehtaDaniel Jerome Monnin — In memory of

Carl Joseph Monnin; In honor of Dr. Jeanne M. Schilder

My Tribute GiftNetwork for GoodBert O’NeilMegan ReimannJessica RoyAnita Rush-TaylorDaniel RushingDavid SamsJennifer SamsJeanne Schilder — In memory of

Kelly McCombs MotzBradley R. SchutzTheodore and Barbara StansburyDonald Vanderkolk — In memory of Sheryl DillingerHeather WarhurstChristopher WayneLisa Leanne Wood — In memory of

Mrs. Alice HoffmanYour Cause LLC (Trustee for Wells Fargo

Community Support Campaign)

Make a lasting difference with a planned giftPlease consider making a gift from your estate to

Hoosier Cancer Research Network. Your generosity

will help ensure researchers have the support they

need to explore critical questions in cancer research.

Learn more: hoosiercancer.org/mylegacy

Our Contributors

AlabamaUAB Comprehensive Cancer Center, Birmingham

ArizonaBCG Oncology, P.C., PhoenixIronwood Cancer & Research Centers, PhoenixUniversity of Arizona Cancer CenterYuma Regional Cancer Center, LLC, Yuma

ArkansasGenesis Cancer Center, Hot Springs

CaliforniaCedars-Sinai Medical Center, Los AngelesCity of Hope, DuarteMarin Cancer Care, GreenbraeMoores Cancer Center at UC San Diego HealthProstate Oncology Specialists, Inc., Marina Del ReySalinas Valley Memorial Healthcare System, SalinasStanford University, StanfordUSC Norris Comprehensive Cancer Center, Los Angeles

ColoradoUniversity of Colorado Cancer Center, Aurora

ConnecticutYale Cancer Center, New Haven

FloridaMemorial Breast Cancer Center at Memorial Regional Hospital,

HollywoodMoffitt Cancer Center, TampaSylvester Comprehensive Cancer Center at the University

of MiamiUF Health Cancer Center, OrlandoUniversity of Florida Health Cancer Center, Gainesville

IllinoisIllinois CancerCare, PC, GalesburgRobert H. Lurie Comprehensive Cancer Center of Northwestern

University, ChicagoRush University Medical Center, ChicagoThe University of Chicago Medical CenterUniversity of Illinois Cancer Center, Chicago

IndianaAmerican Health Network, IndianapolisBaptist Health Floyd Cancer Care Center, New AlbanyCommunity Health Network, Inc. Cancer Centers, IndianapolisCommunity Healthcare System, MunsterFort Wayne Medical Oncology & HematologyGood Samaritan, VincennesGoshen Center for Cancer CareHorizon Oncology Research LLC, LafayetteIndiana University Melvin and Bren Simon Comprehensive Cancer

Center, IndianapolisIU Health Arnett Cancer Centers, LafayetteIU Health Ball Memorial Cancer Center, MuncieIU Health Cancer Centers BloomingtonIU Health Central Indiana Cancer Centers, IndianapolisMemorial Hospital of South Bend and Elkhart General HospitalOncology Hematology Associates of Southwest Indiana, NewburghParkview Research Center, Fort WayneSt. Vincent, IndianapolisSt. Vincent Anderson Regional Hospital, Anderson

IowaUniversity of Iowa Holden Comprehensive Cancer Center, Iowa City

KansasCancer Center of Kansas, WichitaUniversity of Kansas Medical Center, Kansas City

KentuckyUniv. of Louisville/James Brown Cancer Center, Louisville

LouisianaOchsner, New Orleans

MarylandMeritus Center for Clinical Research / John R. Marsh Cancer Center,

HagerstownSidney Kimmel Comprehensive Cancer Center at Johns Hopkins,

BaltimoreUniversity of Maryland Marlene and Stewart Greenebaum

Comprehensive Cancer Center, Baltimore

MassachusettsBeth Israel Deaconess Medical Center, BostonDana-Farber Cancer Institute, BostonTufts Medical Center, Boston

MichiganBarbara Ann Karmanos Cancer Center, DetroitHenry Ford Health System, DetroitMichigan Center of Medical Research, Farmington HillsThe Cancer Center at Metro Health Village, WyomingUniversity of Michigan Rogel Cancer Center, Ann Arbor

MinnesotaHealthPartners Institute, MinneapolisMasonic Cancer Center, Univ. of Minnesota, Minneapolis

MissouriSiteman Cancer Center at Barnes-Jewish Hospital and Washington

University School of Medicine, St. Louis

NebraskaFred & Pamela Buffett Cancer Center (University of Nebraska),

OmahaMethodist Hospital, OmahaNebraska Cancer Specialists, OmahaUrology Cancer Center and GU Research Network, Omaha

New HampshireDartmouth-Hitchcock Norris Cotton Cancer Center, Lebanon

New JerseyAtlantic Health System, MorristownJohn Theurer Cancer Center at Hackensack Meridian Health,

HackensackPenn Medicine | Virtua Cancer ProgramRegional Cancer Care Associates, LLC, Cherry HillRutgers Cancer Institute of New Jersey, New BrunswickSummit Medical Group Cancer Center, Florham Park

New MexicoUniversity of New Mexico Comprehensive Cancer Center,

Albuquerque

New YorkColumbia University Irving Medical Center, New YorkIcahn School of Medicine at Mount Sinai, New YorkIntegrated Medical Professionals, PLLC, Melville

Our Member Network

Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo

Memorial Sloan Kettering Cancer Center, New YorkMontefiore Medical CenterNew York University Cancer Institute, New YorkRoswell Park Cancer Institute, BuffaloUniversity of Rochester - Wilmot Cancer Institute

North CarolinaDuke Cancer InstituteNovant Health Oncology Specialists, Winston-SalemUniversity of North Carolina Lineberger Comprehensive Cancer

Center, Chapel HillWake Forest Baptist Medical Center Comprehensive Cancer Center,

Winston-Salem

OhioCleveland Clinic Cancer CenterThe Ohio State University, ColumbusUniversity Hospitals Seidman Cancer Center, ClevelandUniversity of Cincinnati Cancer Center

OklahomaStephenson Cancer Center at the Univ. of Oklahoma, Oklahoma City

OregonKnight Cancer Institute at Oregon Health & Science University,

PortlandProvidence Cancer Institute, Portland

PennsylvaniaAllegheny Health Network, PittsburghFox Chase Cancer Center, PhiladelphiaGettysburg Cancer Center, GettysburgPenn Medicine Abramson Cancer Center, PhiladelphiaPenn State Cancer Institute, HersheyThomas Jefferson University / Sidney Kimmel Cancer Center,

PhiladelphiaUPMC Hillman Cancer Center, Pittsburgh

South CarolinaMedical University of South Carolina / Hollings Cancer Center,

Charleston

TennesseeErlanger Health System, ChattanoogaVanderbilt-Ingram Cancer Center, NashvilleWest Cancer Center, Memphis

TexasBaylor College of Medicine, HoustonJoe Arrington Cancer Research and Treatment Center, LubbockMD Anderson Cancer Center, HoustonTexas Oncology - Baylor Charles A. Sammons Cancer Center, DallasUT Health San Antonio MD Anderson Cancer CenterUT Medical Branch at GalvestonUT Southwestern Harold C. Simmons Comp. Cancer Center, Dallas

UtahHuntsman Cancer Institute at University of Utah, Salt Lake City

VirginiaUniversity of Virginia Cancer Center, CharlottesvilleVirginia Commonwealth University, RichmondVirginia Oncology Associates, Norfolk

WashingtonFred Hutchinson Cancer Research Center, Seattle

Washington, D.C.George Washington University Cancer CenterGeorgetown University Lombardi Comprehensive Cancer Center

WisconsinAurora Research Institute, LLC, MilwaukeeClement J. Zablocki VA Medical Center, MilwaukeeFroedtert & the Medical College of Wisconsin, MilwaukeeUniversity of Wisconsin Carbone Cancer Center, Madison

Our Member Network

Academic site

Learn more at:hoosiercancer.org/members

500 N. Meridian Street, Suite 100, Indianapolis, IN 46204P: (317) 921-2050 F: (317) 921-2053 E: [email protected]

www.hoosiercancer.org

Date post:	13-Jan-2022
Category:	Documents
Upload:	others
View:	1 times
Download:	0 times

Annual Report 2020 - Hoosier Cancer

Documents